Potential immunotherapeutic strategies either directly addressing AML surface proteins (e.g., CD123) or indirectly activating the innate immune system (e.g., macrophages by targeting CD47) are currently developed as single treatments or in combination with epigenetic therapy. This evidence concerns the gene CD47 and acute myeloid leukemia.